A Phase 2 interventional study of gemcitabine and cisplatin in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 8 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-09.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 5 under way, none of them phase 3. Gemcitabine · Carcinoma, Non-Small-Cell Lung.
Among the 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung, this one is the 83rd largest by enrollment of the 152 interventional ones that give a count, is one of 16 that started in 2004, is one of 109 in phase 2, and was the 49th registered.
7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →4 of the 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:
Swiss Cancer Institute · Sites in Switzerland
Ages 18+
Fox Chase Cancer Center · Sites in United States
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
Hunan Province Tumor Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
169 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 121 · Phase 3 28 · Phase 4 3
First in 1997; this study’s year is marked. 16 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is below the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 53 across the 152 interventional studies. Of the 133 that completed or were terminated, 40 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 169 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 111th largest by enrollment of the 139 interventional ones that give a count, is one of 8 that started in 2004, is one of 73 in phase 2, and was the 20th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the response rate of patients with non small lung cancer to gemcitabine in combination with radiotherapy. The tolerability and safety of this combination will also be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5). Cisplatin: 80 mg/m2, IV, every 21 days x 5 cycles. Radiation: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5.
Drug: gemcitabine · Drug: cisplatin · Radiation: radiation
1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5)
Also known as: LY188011, Gemzar
80 mg/m2, IV, every 21 days x 5 cycles
63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5
Tumor Response at End of Treatment
Response recorded at the first follow-up visit using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
Time frame: baseline to first follow-up visit (up to 8 weeks after end of chemo-radiation)
Time to Progressive Disease
Time to progressive disease is the time from the date of enrollment to the first date of documented disease progression. Patients who have not had disease progression will be censored at the date of the last follow-up visit. Patients dying because of reasons other than tumor progression are not included.
Time frame: Preliminary: baseline to measured progressive disease (up to 3.5 years); Final: baseline to measured progressive disease (up to 5 years);
Overall Survival
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.
Time frame: Preliminary: baseline to date of death from any cause (up to 3.5 years); Final: baseline to date of death from any cause (up to 5 years)
Safety of Induction Chemotherapy
A grading (severity) scale is provided for each adverse event term. Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 2.0 grading scales. Grades range from 0 (none) to 5 (death). Number of participants with clinically significant Grade 3 and Grade 4 toxicities occurring during induction chemotherapy are reported. Grade 3 events are severe and Grade 4 events are life-threatening.
Time frame: every cycle (21 days) for 3 cycles (up to 10 weeks)
Safety of Chemo-radiotherapy
A grading (severity) scale is provided for each adverse event term. Toxicities were graded according to NCI-CTC Version 2.0 grading scales. For specific radiation events, Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation toxicity scale was used. Grades range from 0 (none) to 5 (death). Number of participants with clinically significant acute Grade 3 and Grade 4 toxicities (worst severity) occurring during chemo-radiation and up to 49 days (8 weeks) after are reported. Grade 3 events are severe and Grade 4 events are life-threatening.
Time frame: Cycles 4 and 5 up to 8 weeks after the end of chemo-radiotherapy
| Milestone | Gemcitabine + Cisplatin |
|---|---|
| Started | 49 |
| Completed | 28 |
| Not completed | 21 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Adverse event | 6 |
| Withdrew: Patient/physician perception | 1 |
| Withdrew: Objective tumor progression | 4 |
| Withdrew: Clinical disease progression | 1 |
| Withdrew: Death | 1 |
| Withdrew: Unknown or not specified | 5 |
Response recorded at the first follow-up visit using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
| participants | Gemcitabine + Cisplatin |
|---|---|
| Complete Response | 1 |
| Partial Response | 18 |
| Stable Disease | 3 |
| Progressive Disease | 1 |
| Unknown | 22 |
| Missing | 4 |
Time to progressive disease is the time from the date of enrollment to the first date of documented disease progression. Patients who have not had disease progression will be censored at the date of the last follow-up visit. Patients dying because of reasons other than tumor progression are not included.
| months | Gemcitabine + Cisplatin |
|---|---|
| Preliminary | 10.9 (0.9 to 39.2) |
| Final | 11.4 (9.4 to 12.9) |
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.
| months | Gemcitabine + Cisplatin |
|---|---|
| Preliminary | 27.9 (0.9 to 39.2) |
| Final | 21.8 (17.5 to 26.0) |
A grading (severity) scale is provided for each adverse event term. Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 2.0 grading scales. Grades range from 0 (none) to 5 (death). Number of participants with clinically significant Grade 3 and Grade 4 toxicities occurring during induction chemotherapy are reported. Grade 3 events are severe and Grade 4 events are life-threatening.
| participants | Gemcitabine + Cisplatin |
|---|---|
| Neutropenia - Grade 3 | 9 |
| Neutropenia - Grade 4 | 8 |
| Thrombocytopenia - Grade 3 | 4 |
| Thrombocytopenia - Grade 4 | 1 |
A grading (severity) scale is provided for each adverse event term. Toxicities were graded according to NCI-CTC Version 2.0 grading scales. For specific radiation events, Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation toxicity scale was used. Grades range from 0 (none) to 5 (death). Number of participants with clinically significant acute Grade 3 and Grade 4 toxicities (worst severity) occurring during chemo-radiation and up to 49 days (8 weeks) after are reported. Grade 3 events are severe and Grade 4 events are life-threatening.
| participants | Gemcitabine + Cisplatin |
|---|---|
| Neutropenia - Grade 3 | 6 |
| Neutropenia - Grade 4 | 2 |
| Thrombocytopenia - Grade 3 | 7 |
| Thrombocytopenia - Grade 4 | 1 |
| Radiation Esophagitis - Grade 3 | 4 |
| Radiation Esophagitis - Grade 4 | 0 |
| Radiation Pneumonitis - Grade 3 | 1 |
| Radiation Pneumonitis - Grade 4 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gemcitabine + Cisplatin | — | 13/49 (26.5%) | 48/49 (98%) |
| Event | Gemcitabine + Cisplatin |
|---|---|
| Radiation oesophagitisInjury, poisoning and procedural complications | 4/49 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/49 |
| NeutropeniaBlood and lymphatic system disorders | 2/49 |
| VomitingGastrointestinal disorders | 2/49 |
| Radiation pneumonitisInjury, poisoning and procedural complications | 2/49 |
| AnorexiaMetabolism and nutrition disorders | 2/49 |
| LeukopeniaBlood and lymphatic system disorders | 1/49 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/49 |
| Atrial fibrillationCardiac disorders | 1/49 |
| DysphagiaGastrointestinal disorders | 1/49 |
| Event | Gemcitabine + Cisplatin |
|---|---|
| NauseaGastrointestinal disorders | 34/49 |
| AnaemiaBlood and lymphatic system disorders | 32/49 |
| NeutropeniaBlood and lymphatic system disorders | 29/49 |
| VomitingGastrointestinal disorders | 28/49 |
| LeukopeniaBlood and lymphatic system disorders | 22/49 |
| LymphopeniaBlood and lymphatic system disorders | 22/49 |
| ThrombocytopeniaBlood and lymphatic system disorders | 22/49 |
| FatigueGeneral disorders | 21/49 |
| ConstipationGastrointestinal disorders | 19/49 |
| AnorexiaMetabolism and nutrition disorders | 16/49 |
| Age Continuous(years) | Gemcitabine + Cisplatin |
|---|---|
| Mean | 63.1 ± 8.41 |
| Sex: Female, Male(Participants) | Gemcitabine + Cisplatin |
|---|---|
| Female | 13 |
| Male | 36 |
| Region of Enrollment(participants) | Gemcitabine + Cisplatin |
|---|---|
| Belgium | 49 |
| Basis for Pathological Diagnosis(participants) | Gemcitabine + Cisplatin |
|---|---|
| Histopathological | 39 |
| Cytological | 10 |
| Disease Stage(participants) | Gemcitabine + Cisplatin |
|---|---|
| Stage IIIA | 14 |
| Stage IIIB | 35 |
| Karnofsky Performance Status Scale(participants) | Gemcitabine + Cisplatin |
|---|---|
| 80 - Activity with effort; some signs of disease | 9 |
| 90 - Normal activity; minor signs of disease | 24 |
| 100 - Normal no complaints; no evidence of disease | 16 |
| Pathological Diagnosis(participants) | Gemcitabine + Cisplatin |
|---|---|
| Adenocarcinoma of Lung | 18 |
| Large Cell | 7 |
| Other Pathological Diagnosis | 2 |
| Squamous Cell | 22 |
| Time Since Diagnosis(months) | Gemcitabine + Cisplatin |
|---|---|
| Mean | 0.5 ± 0.25 |
The record gives a start of Aug 2004, a primary completion of Jan 2008 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gemcitabine · Cisplatin
Carcinoma, Non-Small-Cell Lung →